CANDICE GRACE-LEE: Open Payments
NPI 1023070414 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 32 payments from 13 companies in 2025. Trend: 2023 $522 · 2024 $354 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $158 |
| Lundbeck LLC | 5 | $116 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $80 |
| Otsuka America Pharmaceutical, Inc. | 2 | $61 |
| E.R. Squibb & Sons, L.L.C. | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
Products named: INGREZZA, REXULTI, HETLIOZ, CAPLYTA, Sunosi, COBENFY, SPRAVATO, Qelbree.
Industry payments across MD — which companies pay providers there.
